Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2-Reference-Cited by-同舟云学术

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

Published:2023-12 Issue:12 Volume:34 Page:1131-1140
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Damodaran S.,O’Sullivan C.C.,Elkhanany A.,Anderson I.C.,Barve M.,Blau S.,Cherian M.A.,Peguero J.A.,Goetz M.P.,Plourde P.V.,Portman D.J.,Moore H.C.F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference71 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER Database;Hwang;Clin Cancer Res,2019

3. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021

4. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline Update;Burstein;J Clin Oncol,2021

5. The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy;De Santo;Cancers (Basel),2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23

3. Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer;Journal of Clinical Medicine;2024-06-20

4. Significance of Multi-Cancer Genome Profiling Testing for Breast Cancer: A Retrospective Analysis of 3326 Cases from Japan’s National Database;Genes;2024-06-17

5. Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer;Breast Cancer Research;2024-06-07